December 11, 2013
GlaxoSmithKline K.K. (GSK) launched on December 9 its bronchial asthma combination treatment Relvar 100 Ellipta 14 Inhalations/Relvar 200 Ellipta 14 Inhalations (fluticasone furoate + vilanterol trifenatate). The drug is a fixed-dose combination of the company’s allergic rhinitis treatment Allermist (fluticasone),...read more